These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15836868)

  • 1. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
    Pagotto U; Pasquali R
    Lancet; 2005 Apr 16-22; 365(9468):1363-4. PubMed ID: 15836868
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on rimonabant--a selective cannabinoid CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915
    [No Abstract]   [Full Text] [Related]  

  • 3. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 4. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
    Boekholdt SM; Jukema JW; Peters RJ
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
    Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
    Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New drugs; rimonabant].
    van Bronswijk H; Dubois EA; Pijl H; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rimonabant actions on cardiometabolic risk factors].
    Stiefelhagen P
    Med Monatsschr Pharm; 2007 Jan; 30(1):39-40. PubMed ID: 17260652
    [No Abstract]   [Full Text] [Related]  

  • 9. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocannabinoid system and cardiometabolic risk.
    Saavedra LE
    Clin Pharmacol Ther; 2007 Nov; 82(5):591-4. PubMed ID: 17898706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
    Banasch M; Goetze O; Schmidt WE; Meier JJ
    Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
    [No Abstract]   [Full Text] [Related]  

  • 12. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?
    Maccarrone M; Wang H; Dey SK
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):456-7. PubMed ID: 17302885
    [No Abstract]   [Full Text] [Related]  

  • 14. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
    Andrikopoulos GK; Tzeis S
    Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rimonabant and progression of atherosclerosis in obese persons.
    Dora JM; Scheffel RS
    JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
    [No Abstract]   [Full Text] [Related]  

  • 16. ADAGIO-Lipids gives promises but faces the setbacks.
    Taskinen MR
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):339-40. PubMed ID: 19228609
    [No Abstract]   [Full Text] [Related]  

  • 17. [Nutrition-obesity. Rimonabant and cardiovascular risk factors].
    Vincent M; Golay A
    Rev Med Suisse; 2009 Jan; 5(185):49-52. PubMed ID: 19216325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
    Cota D; Genghini S; Pasquali R; Pagotto U
    J Endocrinol Invest; 2003 Oct; 26(10):1041-4. PubMed ID: 14759080
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
    MMW Fortschr Med; 2006 Aug; 148(35-36):48. PubMed ID: 16995368
    [No Abstract]   [Full Text] [Related]  

  • 20. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.